Aktuellt
SENASTE
Redeye endorses today’s news that Herantis has received approval to start its phase I study with HER-096 in healthy volunteers. To us, the step back into the clinic has been an important milestone and we like that the timeline continues to be followed. We will discuss the trial further in relation to the H2 report.
LÄS MER
